

## A Message from Paul Lucas President & CEO, GlaxoSmithKline Inc.

*GSK's ability to innovate means that our company can make a truly meaningful contribution to the lives of Canadians. Through discoveries made in laboratories, we are able to help treat those suffering with diseases such as asthma, depression, diabetes and HIV/AIDS.*

*While innovation may begin in the laboratory and within educational institutions, it continues to be a focus across the entire GSK organization. In addition to a substantial R&D commitment, our investments in valued community partners like hospitals, universities and research facilities help to foster advancements in health sciences.*

*GSK's accomplishments and contributions would be impossible without government efforts to create a supportive environment for the research-based pharmaceutical industry. We look forward to another 100 years of improving the lives of Canadians, creating high-value jobs, delivering innovative medicines and investing in our community.*

## GlaxoSmithKline Celebrates 100 Years In Canada

GlaxoSmithKline Inc. (GSK) recently celebrated 100 years in Canada, a significant milestone in its evolution from humble beginnings as a single apothecary shop. Since 1902, GSK has grown into a leading healthcare company that has helped to improve the lives of millions of Canadians through the discovery of innovative medicines and healthcare solutions.

This commitment to leadership extends to community investment, where GSK has established itself as one of the country's top 10 corporate charitable donors, donating more than \$7.5 million annually. To mark its 100-year anniversary in Canada, GSK made two separate \$1 million donations to The Credit Valley Hospital and Trillium Health Centre.

These healthcare facilities will use their respective donations to provide significantly enhanced support and services for their current asthma education and community awareness programs, including those that are geared towards children and youth.

■ continued on reverse



To commemorate GSK's 100-year anniversary in Canada, a maple tree was planted at GSK's headquarters in Mississauga by Ken White, President and CEO, Trillium Health Centre, Wayne Fyffe, President and CEO, The Credit Valley Hospital, Mayor Hazel McCallion, City of Mississauga, Paul Lucas, President and CEO, GlaxoSmithKline, Colleen Beaumier, MP and two young residents of Mississauga who have asthma, Sofia Rokerya and Michael Gizzi.



# Research Chair Brings New Hope for Kids With Asthma

More than two million Canadians suffer from asthma, a debilitating disease that places a tremendous burden on the Canadian healthcare system and is rising in prevalence, particularly amongst children.

As a leader in asthma care, GSK recently made a \$1 million investment to establish the GlaxoSmithKline Research Chair in Pediatric Asthma at the Firestone Institute for Respiratory Health, St. Joseph's Healthcare Hamilton and McMaster University.

The creation of this chair will enable the Firestone Institute to create a permanent position, allowing the recipient to conduct research that will improve the understanding of this chronic disease and potentially lead to pioneering new treatments for Canadian children with asthma.

This endowed research chair is part of *GSK's Pathfinders Fund for Leaders in*

*Canadian Health Science Research*, a \$20 million initiative to help fight the brain drain in Canada by providing opportunities for leading medical researchers and scientists. The goal of the fund is to establish research positions at all 16 medical schools across the country. Already, the Pathfinders Fund has helped establish more than 10 research chairs at universities in five provinces.

"This Research Chair recognizes the role of the Firestone Institute in providing leading-edge research into asthma and other respiratory diseases," said Dr. Paul O'Byrne, Director of the Firestone Institute for Respiratory Health and Head of the Division of Respiratory Medicine at McMaster University. "The investment will enable the future recipient of this Research Chair to establish a world-class centre for the study of pediatric asthma."

## FACTS ABOUT ASTHMA:

Asthma affects an estimated 10 to 15 per cent of Canadian children.

Approximately 450 Canadians die each year from asthma.

It is estimated that more than 80 per cent of asthma-related deaths could be prevented with proper education and treatment.

## GSK Celebrates 100 Years In Canada

continued from cover

GSK has also emerged as a leader in research and development (R&D) dedicated to excellence in Canadian health sciences. The company currently contributes over \$100 million dollars to R&D each year, making it one of the top 25 corporate contributors in Canada.

"GSK is unquestionably a leader in Canada's healthcare community," says Dr. Colin F. Saldanha, Medical Director, Peel Travel Clinic, who participated in GSK's 100-year event. "I've had the opportunity to see



**Dr. Colin F. Saldanha**  
Medical Director,  
Peel Travel Clinic

disease management evolve over the past 14 years. Companies like GSK have contributed to the improvement of the quality of life of my patients by creating new products for asthma, diabetes, depression and migraine headaches."

By continuing to develop innovative medicines and make strong community investments, GSK will build upon its legacy as a company committed to improving the lives of Canadians.

## GlaxoSmithKline in Canada

GlaxoSmithKline is committed to bringing the power of science to the needs of people to help them do more, feel better and live longer. GlaxoSmithKline is a leader in four major therapeutic areas — anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic, as well as in the increasingly important area of vaccines.

GlaxoSmithKline Corporate Communications 905-819-3000